Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 14/20 | 1.00 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.56 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.53 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7974925 | 1.00 | CTSD (1.00) | CTSDMMP13ADAMTS5CYSLTR2CYSLTR1 | |
| SCHEMBL7971394 | 0.90 | CTSD (1.00) | CTSDCYSLTR2CYSLTR1 | |
| SCHEMBL7971391 | 0.90 | CTSD (1.00) | CTSDCYSLTR2CYSLTR1 | |
| SCHEMBL7968171 | 0.89 | CTSD (0.98) | CTSDCYSLTR2CYSLTR1 | |
| SCHEMBL7968016 | 0.89 | CTSD (0.98) | CTSDCYSLTR2CYSLTR1 | |
| SCHEMBL7968173 | 0.89 | CTSD (0.98) | CTSDCYSLTR2CYSLTR1 | |
| Lithium SCHEMBL7968174 | 0.89 | CTSD (0.98) | CTSDCYSLTR2CYSLTR1 | |
| SCHEMBL7968009 | 0.89 | CTSD (0.98) | CTSDCYSLTR2CYSLTR1 | |
| SCHEMBL7968013 | 0.89 | CTSD (0.98) | CTSDCYSLTR2CYSLTR1 | |
| SCHEMBL7971872 | 0.83 | CTSD (0.81) | CTSDADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6251928-B1 | ADMINISTERING BENZYLIDENE RHODANINES WHICH ARE USEFUL AS AGENTS IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH BETA-AMYLOID PEPTIDE IN A MAMMAL | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0677517-A1 | Treatment of Alzheimer's disease employing inhibitors of cathepsin D | ELI LILLY AND COMPANY (US) | 1995-10-18 | — | — | EP | disclosed |